Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Targeting specific histone deacetylase may be novel therapeutic strategy for NSCLC

The survival rates for patients with non-small cell lung cancer have improved greatly over the past decade thanks to several new targeted treatment options for patients.

26 Mar 2020

FDA approves immune-modulating therapy for treatment of multiple sclerosis

The U.S. Food and Drug Administration has approved ozanimod, an immune-modulating therapy invented at Scripps Research, for the treatment of adults with relapsing forms of multiple sclerosis.

26 Mar 2020

Transmission of COVID-19 among cancer patients in China

Researchers from Zhongnan Hospital of Wuhan University in China in collaboration with those from the National Cancer Centre Singapore, have come up with a study that reveals the transmission of the SARS-CoV-2 or novel coronavirus among patients with cancer in China.

25 Mar 2020

Study shows disparities in guideline-concordant treatment for NSCLC patients

Lung cancer is the leading cause of cancer-associated deaths in the United States. Non-small cell lung cancer (NSCLC), a group of lung cancers named for the kinds of cells found in the cancer, constitutes more than 80% of all lung cancer cases.

25 Mar 2020

Gero uses AI platform to identify potential anti-COVID-19 drugs

Gero, the leader in AI-driven drug discovery, has used its AI platform to identify the potential anti-COVID-19 drugs. Six of them have been approved, three were withdrawn, and the other nine have been already tested in clinical trials for other indications.

25 Mar 2020

Lung cancer medication may have benefits for patients with metastatic brain cancers

A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St. Michael's Hospital of Unity Health Toronto and Harvard Medical School.

25 Mar 2020

Penn State engineers model genetic mutations causing drug resistance

Whether it is a drug-resistant strain of bacteria, or cancer cells that no longer react to the drugs intended to kill them, diverse mutations make cells resistant to chemicals, and "second generation" approaches are needed.

24 Mar 2020

AI could enhance prediction of treatment response among patients with non-small cell lung cancer

Artificial intelligence deep learning algorithms may predict response to systemic treatment for non-small cell lung cancer.

23 Mar 2020

Plasma monitoring of EGFR mutations in NSCLC may help predict resistance to tyrosine kinase inhibitors

Oncotarget Volume 11, Issue 11 reported that at clinical progression, 64 EGFR T790M plasma positive patients were subjected to second line-treatment with osimertinib and strictly monitored during the first month of therapy.

22 Mar 2020

AI may help predict tumor sensitivity to systemic cancer therapies

Using standard-of-care computed tomography scans in patients with advanced non-small cell lung cancer, researchers utilized artificial intelligence to train algorithms to predict tumor sensitivity to three systemic cancer therapies.

20 Mar 2020

New marker may predict whether NSCLC tumor is likely to metastasize

Non-small cell lung cancer (NSCLC) is the most commonly diagnosed cancer, and the leading cause of cancer death worldwide.

11 Mar 2020

African American, Hispanic lung cancer patients less likely to receive PET-CT imaging

The use of PET-CT imaging gives doctors the best possible picture of non-small cell lung cancer, and this accurate imaging helps to match patients with the best treatments.

11 Mar 2020

Biomarkers in blood samples can predict clinical response to immunotherapy in metastatic NSCLC

Non-small cell lung cancer patients with higher measures of tumor mutations that show up in a blood test generally have a better clinical response to PD-1-based immunotherapy treatments than patients with a lower measure of mutations.

26 Feb 2020

UT Dallas scientists awarded CPRIT grants for lung, kidney cancer research

The Cancer Prevention and Research Institute of Texas has awarded new grants totaling $1.8 million to two University of Texas at Dallas scientists for their research related to lung and kidney cancers.

23 Feb 2020

Administering immunotherapy alongside chemoradiation for advanced NSCLC appears to be safe and tolerable

Research from Rutgers Cancer Institute of New Jersey shows administering the immunotherapy drug pembrolizumab together with chemotherapy given at the same time as radiation treatment (chemoradiation) is safe and tolerable as a first-line therapy for patients with stage 3 non-small cell lung cancer.

21 Feb 2020

Global study shows long-term survival benefit for a subset of patients with advanced lung cancer

According to the results of a large, global study led by Yale Cancer Center researchers, even a tiny amount of a biomarker known as PD-L1 (programmed death-ligand1) can predict a long-term survival benefit from using pembrolizumab (Keytruda).

20 Feb 2020

Intratumoral heterogeneity linked to chemotherapy resistance in small-cell lung cancer

Small cell lung cancer accounts for 14% of all lung cancers and is often rapidly resistant to chemotherapy, resulting in poor clinical outcomes.

17 Feb 2020

New summary report highlights advances and challenges in small cell lung cancer research

In 2017, a group of lung cancer experts posed the question: "Can recent advances in tumor biology that have led to progress treating non-small cell lung cancer translate into improved outcomes for small cell lung cancer?"

10 Feb 2020

Purdue-developed 'fluorescent markers' begin Phase 3 clinical trials

On Target Laboratories Inc., a privately held biotechnology company developing the use of Purdue University-discovered fluorescent markers to target and illuminate cancer during surgery, has announced the results of a multi-institutional Phase 2 clinical trial in which outcomes were improved for 26% of patients undergoing pulmonary resection for non-small-cell lung cancer.

6 Feb 2020

Analysis shows overall survival in lung cancer patients harboring 'niche' mutations

Mutations were observed in all genes studied, except c-MET, DDR2, MAP2K1, and RET.

5 Feb 2020

Small Cell Lung Cancer News and Research

Targeting specific histone deacetylase may be novel therapeutic strategy for NSCLC

FDA approves immune-modulating therapy for treatment of multiple sclerosis

Transmission of COVID-19 among cancer patients in China

Study shows disparities in guideline-concordant treatment for NSCLC patients

Gero uses AI platform to identify potential anti-COVID-19 drugs

Lung cancer medication may have benefits for patients with metastatic brain cancers

Penn State engineers model genetic mutations causing drug resistance

AI could enhance prediction of treatment response among patients with non-small cell lung cancer

Plasma monitoring of EGFR mutations in NSCLC may help predict resistance to tyrosine kinase inhibitors

AI may help predict tumor sensitivity to systemic cancer therapies

New marker may predict whether NSCLC tumor is likely to metastasize

African American, Hispanic lung cancer patients less likely to receive PET-CT imaging

Biomarkers in blood samples can predict clinical response to immunotherapy in metastatic NSCLC

UT Dallas scientists awarded CPRIT grants for lung, kidney cancer research

Administering immunotherapy alongside chemoradiation for advanced NSCLC appears to be safe and tolerable

Global study shows long-term survival benefit for a subset of patients with advanced lung cancer

Intratumoral heterogeneity linked to chemotherapy resistance in small-cell lung cancer

New summary report highlights advances and challenges in small cell lung cancer research

Purdue-developed 'fluorescent markers' begin Phase 3 clinical trials

Analysis shows overall survival in lung cancer patients harboring 'niche' mutations

Why Primary Cells Are Important for In Vitro ADME-Tox Studies

Recognizing CDKL5 Deficiency Disorder

Isolating Single T-cells of Interest using an Optofluidic Platform

Latest News